Page 1

Jasper THERAPEUTICS INC . Jasper Therapeutics Announces Third Quarter 2021 Financial Results and Provides Business Update November 12 , 2021 REDWOOD CITY , Calif . , Nov. 12 , 2021 ( GLOBE NEWSWIRE ) -- Jasper Therapeutics , Inc. ( Nasdaq : JSPR ) , a biotechnology company focused on hematopoietic cell transplant therapies , today announced results for the quarter ended September 30 , 2021 , and provided a business update . Highlights of the quarter and recent weeks include : • Successful completion of the Company's public listing ( Nasdaq : JSPR ) on September 27 , 2021 following the business combination with Amplitude Healthcare Acquisition Corporation ( AMHC ) on September 24 , 2021 • Receipt of $ 100 million in gross proceeds through the closing of the concurrent companion PIPE transaction • Enrollment of JSP191 Phase 1b study expansion cohorts in acute myeloid leukemia / myelodysplastic syndrome ( AML / MDS ) on track ; top - line interim data expected Q1 2022 • JSP191 Phase 1b severe combined immunodeficiency ( SCID ) study data accepted for presentation at the American Society of Hematology ( ASH ) conference in December 2021 • Phase 1b SCID study resumed enrollment following COVID - 19 - related delays as a precaution for SCID patients • Announced non - exclusive research collaboration with Aruvant Sciences , Inc. to evaluate JSP191 in Sickle Cell Disease gene therapy studies • Announced non - exclusive research collaboration with AVROBIO , Inc. to evaluate JSP191 in Fabry disease and Gaucher disease gene therapy studies • Receipt of FDA Orphan designation for JSP191 for conditioning treatment prior to hematopoietic stem cell transplantation and Rare Pediatric Disease designation for JSP191 as a conditioning treatment for patients with SCID • Initiation of a new Phase 1/2 clinical trial with the National Cancer Institute ( NCI ) to evaluate the use of JSP191 as a targeted , non - toxic conditioning agent in patients with GATA2 - related myelodysplastic syndromes • Successful therapeutic stem cell program in - vitro experiments : engineering of hematopoietic stem cells with mRNA of cell surface protein known to improve stem cell function • Appointment of Lawrence Klein , Ph.D. , and Chris Nolet to the Company's board of directors " Our third quarter has been a transformative period for Jasper , during which we became a Nasdaq - listed company , secured $ 100 million of gross proceeds in new capital , continued to have success in advancing JSP191 in clinical trials , established proof of concept in our research - stage therapeutic stem cell platform and signed two additional corporate partnerships , " said Bill Lis , executive chairman and chief executive officer of Jasper Therapeutics . " As a result , we are now poised for the next stage of success towards transforming the field with upcoming milestones , including : JSP191 AML / MDS top line data in broader patient cohorts with long term follow - up , additional long - term JSP191 data in SCID patients , initiation of a pilot study of JSP191 in autoimmune disease , in - vivo proof of concept data in our therapeutic stem cell program using mRNA cell engineering , initiation of corporate partner gene therapy studies as well as enrollment into academic partner studies across multiple indications . " Third Quarter 2021 Financial Results • Cash and Cash Equivalents : Cash and cash equivalents as of September 30 , 2021 , were $ 100.9 million . The Company expects current cash and cash equivalents to be sufficient to fund its planned operating and capital expenditures through mid - 2023 . • Research and Development ( " R & D " ) Expenses : R & D expenses for the three and nine months ended September 30 , 2021 were $ 7.2 million and $ 16.8 million , respectively as compared to $ 4.5 million and $ 11.2 million , respectively , for the same periods in 2020. The increases were primarily due to additional costs associated to advancing our clinical trials and clinical manufacturing expenses . The increases also relate to higher employee headcount to support ongoing development of our product candidates . • General and Administrative ( " G & A " ) Expenses : G & A expenses for the three and nine months ended September 30 , 2021 were $ 2.9 million and $ 8.0 million , respectively , as compared to $ 1.5 million and $ 3.5 million , respectively , for the same periods in 2020. The increases were primarily related to professional fees , employee compensation related expenses , including stock - based compensation , supporting the growth in our operations and costs associated with being a public company .